Officials break ground on new pharmaceutical facility in Smithfield

Share on Social Media

SMITHFIELD, R.I. (WPRI) — Work is now officially underway on a new pharmaceutical company after several state officials gathered to break ground on the project Wednesday afternoon.

Once completed, the new Rubius Therapeutics facility will support 160 new jobs in manufacturing, biotech operations and other support functions.

Governor Gina Raimondo, officials from the Rhode Island Commerce Corporation and Rubius Therapeutics CEO Dr. Pablo Cagnoni broke ground on the project Wednesday.

“The Rhode Island Commerce Corporation and Governor Raimondo have an impressive and growing track record of attracting top biotechnology companies and creating high paying jobs,” Cagnoni said. “I am happy to be able to say that Rubius Therapeutics is now a part of this booming ecosystem of biotechnology innovation.”

Founded in 2013, Rubius Therapeutics is developing treatments for cancer and other diseases using a new technology it calls Red Cell Therapeutics. The company plans to invest up to $155 million over approximately five years to renovate an existing 135,000 square-foot building in Smithfield.

“Thanks to our investments in economic development and skills training, Rhode Island’s biotechnology industry is on the rise,” Raimondo said. “Rubius is a leader in their field, and I’m thrilled that they’re investing in our state and creating 160 good-paying jobs here in Smithfeld.”

Rubius Therapeutics will take the place of Alexion Pharmaceuticals, who previously owned the facility. The company announced in January they were buying the facility from Alexion.

According to Appleseed, a third-party economic analysis firm, the new facility is projected to add $6.34 million in net revenue to the state over the 12-year commitment period and increase the state’s GDP by $28.1 million annually.

“We are very pleased that Rubius Therapeutics has broken ground on its new advanced manufacturing facility,” Rhode Island Secretary of Commerce Stefan Pryor said. “Rubius joins companies such as Amgen, Johnson & Johnson, and EpiVax in our flourishing bioscience ecosystem. We congratulate Rubius on this milestone and look forward to the company’s success here.”

Latest News

Why We’re Still in a Providence State of Mind

Why We’re Still in a Providence State of Mind

We can count on Bisnow to shine a light on great things happening in Rhode Island. Last year, the group’s “New England Presents” series included a panel called “Investing in Rhode Island.” This year, Bisnow hosted “Providence State of the Market,” which brought...

Apply for the SEG Incubator

Apply for the SEG Incubator

Have an idea for a business that positively impacts the community? Turn your idea into action with our Incubator program. This three week business education program includes 6 in person workshops, one-on-one customized coaching, and a cohort of fellow entrepreneurs to...

Putting the Patient First with Asthenis Pharmacy

Putting the Patient First with Asthenis Pharmacy

October 15, 2018 Walking into Asthenis, one is immediately struck by the beauty of the facility. The vibrant purple and green logo grabs your attention, and the modern decor makes the pharmacy unique and inviting. The owner of Asthenis, Dr. Eugenio Fernandez Jr.,...

Now Online:  NIH Clinical Research Courses

Now Online: NIH Clinical Research Courses

The NIH Office of Clinical Research is offering free, self-paced online clinical research courses. The courses are: Introduction to the Principles and Practice of Clinical Research; and Principles of Clinical Pharmacology. Registration and participation for both...

Biotech Industry News